SBV Journal of Basic, Clinical and Applied Health Science

Register      Login

VOLUME 2 , ISSUE 3 ( July–September, 2019 ) > List of Articles


Changes in Renal Disease: A Vascular Perspective

Rebecca Lefroy, Nikesh Dattani, Fatemeh Sakhinia, Julien Al Shakarchi, Anthony Jaipersad, Arun Pherwani

Keywords : Renal disease, Renal replacement therapy, Vascular access

Citation Information : Lefroy R, Dattani N, Sakhinia F, Al Shakarchi J, Jaipersad A, Pherwani A. Changes in Renal Disease: A Vascular Perspective. 2019; 2 (3):89-94.

DOI: 10.5005/jp-journals-10082-02219

License: CC BY-NC 4.0

Published Online: 18-07-2020

Copyright Statement:  Copyright © 2019; The Author(s).


This paper aims to review and discuss important advances in renal medicine that have occurred in the last 50 years. This has shaped the way that patients with end-stage renal failure (ESRF) are managed, with emphasis on renal replacement therapy (RRT), and has resulted in wide-reaching improvements in each patient’s journey. These changes have been summarized in an easily accessible form and addressed from the perspective of the United Kingdom.

  1. Public Health England. Chronic kidney disease prevalence model; 2014. pp. 1–6.
  2. Hospital S, Road S. UK Renal Registry 19th Annual Report; 2017.
  3. Collins AJ, Foley RN, Gilbertson DT, Chen SC. The state of chronic kidney disease, ESRD, and morbidity and mortality in the first year of dialysis. Clin J Am Soc Nephrol 2009;4(Suppl 1):S5–S11. DOI: 10.2215/CJN.05980809.
  4. National Kidney Foundation. Clinical practice guidelines for vascular access. Am J Kidney Dis 2006;48(Suppl 1):487–488.
  5. NKF-DOQI clinical practice guidelines for vascular access and anemia of chronic renal failure: introduction. Am J Kidney Dis 1997;30:S152–S153. DOI: 10.1016/S0272-6386(97)90251-1.
  6. Kumwenda M, Sandip M, Reid C. Clinical Practice Guideline—Vascular Access for Haemodialysis; 2017.
  7. Renal Update [Internet]. Best Practice Advocacy centre New Zealand. 2018. Available from:
  8. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39:S1–S266.
  9. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–S266.
  10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41. DOI: 10.1159/000180580.
  11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999;130:461–470. DOI: 10.7326/0003-4819-130-6-199903160-00002.
  12. Robson J, Dostal I, Sheikh A, Eldridge S, Madurasinghe V, Griffiths C, et al. The NHS health check in England: an evaluation of the first 4 years. BMJ Open 2016;6(1):e008840. DOI: 10.1136/bmjopen-2015-008840.
  13. Manns B, Hemmelgarn B, Tonelli M, Au F, Chiasson TC, Dong J, et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ 2010;341:c5869. DOI: 10.1136/bmj.c5869.
  14. Ruf M, Morgan KM. Planning, operation and evaluation of screening [Internet]. 2017. Available from:
  15. Van Buren PN, Toto R. Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management. Adv Chronic Kidney Dis 2011;18(1):28–41. DOI: 10.1053/j.ackd.2010.10.003.
  16. McCarley PB, Burrows-Hudson S. Chronic kidney disease and cardiovascular disease--using the ANNA standards and practice guidelines to improve care. Part 1: the epidemiology of chronic kidney disease: the risk factors and complications that contribute to cardiovascular disease. Nephrol Nurs J 2006;33(6):666–674.
  17. Garimella PS, Uhlig K. Current issues in the management and monitoring of hypertension in chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22(6):599–606. DOI: 10.1097/MNH.0b013e328365addf.
  18. Brosnahan G. Treatment of hypertension in chronic kidney disease: does one size fit all? A narrative review from a nephrologist’s perspective. Curr Hypertens Rev 2014;10(3):155–165. DOI: 10.2174/1573402111666150108101104.
  19. Stephan D, Gaertner S, Cordeanu EM. A critical appraisal of the guidelines from France, the UK, Europe and the USA for the management of hypertension in adults. Arch Cardiovasc Dis 2015;108(8–9):453–459. DOI: 10.1016/j.acvd.2015.05.006.
  20. Mule G, Castiglia A, Cusumano C, Scaduto E, Geraci G, Altieri D, et al. Subclinical kidney damage in hypertensive patients: a renal window Opened on the cardiovascular system. Focus on microalbuminuria. Adv Exp Med Biol 2017;956:279–306.
  21. The ACE Inhibitors in Diabetic Nephropathy Trialist Group* TACEI. Should all patients with type 1 diabetes Mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors?: a meta-analysis of individual patient data. Ann Intern Med 2001;134(5):370–379. DOI: 10.7326/0003-4819-134-5-200103060-00009.
  22. Jerums G, MacIsaac RJ. Treatment of microalbuminuria in patients with type 2 diabetes Mellitus. Treat Endocrinol 2002;1(3):163–173. DOI: 10.2165/00024677-200201030-00004.
  23. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane database Syst Rev 2013(9):CD004289. DOI: 10.1002/14651858.CD004289.pub5.
  24. Anderson TJ, Gregoire J, Hegele RA, Couture P, Mancini GBJ, McPherson R, et al. 2012 Update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol 2013;29(2):151–167. DOI: 10.1016/j.cjca.2012.11.032.
  25. Official Journal of the International Society of Nephrology. KDIGO clinical practice guideline for lipid management in chronic kidney disease KDIGO clinical practice guideline for lipid management chronic kidney disease; 2013; vol. 3, iss. 3.
  26. Orth SR. Smoking—a renal risk factor. Nephron 2000;86(1):12–26. DOI: 10.1159/000045708.
  27. Eknoyan G. Chronic kidney disease definition and classification: the quest for refinements. Kidney Int 2007;72(10):1183–1185. DOI: 10.1038/
  28. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351(13):1296–1305. DOI: 10.1056/NEJMoa041031.
  29. Dinwiddie LC. Investing in the lifeline: the value of a vascular access coordinator. Nephrol News Issues 2003;17(6):49, 52–53.
  30. Almasri J, Alsawas M, Mainou M, Mustafa RA, Wang Z, Woo K, et al. Outcomes of vascular access for hemodialysis: a systematic review and meta-analysis. J Vasc Surg 2016;64(1):236–243. DOI: 10.1016/j.jvs.2016.01.053.
  31. Silva MBJ, Hobson 2nd RW, Pappas PJ, Haser PB, Araki CT, Goldberg MC, et al. Vein transposition in the forearm for autogenous hemodialysis access. J Vasc Surg 1997;26(6):981–986; discussion 987-8 10.1016/S0741-5214(97)70010-7.
  32. Jennings WC, Sideman MJ, Taubman KE, Broughan TA. Brachial vein transposition arteriovenous fistulas for hemodialysis access. J Vasc Surg 2009;50(5):1121–1126. DOI: 10.1016/j.jvs.2009.07.077.
  33. Kakkos SK, Haddad GK, Weaver MR, Haddad RK, Scully MM. Basilic vein transposition: what is the optimal technique? Eur J Vasc Endovasc Surg 2010;39(5):612–619. Available from: 10.1016/j.ejvs.2010.01.006.
  34. Nguyen TH, Bui TD, Gordon IL, Wilson SE. Functional patency of autogenous AV fistulas for hemodialysis. J Vasc Access 2007;8(4):275–280. Available from: 10.1177/112972980700800410.
  35. Shibutani S, Obara H, Ono S, Kakefuda T, Kitagawa Y. Transposed Brachiobasilic arteriovenous fistula. Ann Vasc Dis 2013;6(2):164–168. DOI: 10.3400/avd.oa.13-00042.
  36. Rao RK, Azin GD, Hood DB, Rowe VL, Kohl RD, Katz SG, et al. Basilic vein transposition fistula: a good option for maintaining hemodialysis access site options? J Vasc Surg 2004;39(5):1043–1047. DOI: 10.1016/j.jvs.2004.01.024.
  37. NKF-DOQI clinical practice guidelines for vascular access. National Kidney Foundation-dialysis outcomes quality initiative. Am J Kidney Dis 1997;30(4 Suppl 3):S150–S191.
  38. Verhallen AM, Kooistra MP, van Jaarsveld BC. Cannulating in haemodialysis: rope-ladder or buttonhole technique? Nephrol Dial Transplant 2007;22(9):2601–2604. Available from 10.1093/ndt/gfm043.
  39. Twardowski Z, Kubara H. Different sites vs constant site of needle insertion into arteriovenous fistulas for treatment by repeated dialysis 1979; 8:978–980.
  40. Twardowski ZJ. Constant site (buttonhole) method of needle insertion for hemodialysis. Dial Transplant 2011;40(10):441–443. Available from 10.1002/dat.20621.
  41. Kronung G. Plastic deformation of Cimino fistula by repeated puncture. Dial Transpl 1984;13:635–638.
  42. Abraham G, Varughese S, Mathew M, Vijayan M. A review of acute and chronic peritoneal dialysis in developing countries. Clin Kidney J 2015;8:310–317. DOI: 10.1093/ckj/sfv029.
  43. Bargman JM. Advances in peritoneal dialysis: a review. Semin Dial 2012;25(5):545–549. DOI: 10.1111/j.1525-139X.2012.01124.x.
  44. Power A, Ashby D. Haemodialysis: hospital or home? Postgrad Med J 2014;90(1060):92–97. DOI: 10.1136/postgradmedj-2012-131405.
  45. Nitsch D, Steenkamp R, Tomson CRV, Roderick P, Ansell D, MacGregor MS. Outcomes in patients on home haemodialysis in England and wales, 1997–2005: a comparative cohort analysis. Nephrol Dial Transplant 2011;26(5):1670–1677. DOI: 10.1093/ndt/gfq561.
  46. Gonzalez-Perez JG, Vale L, Stearns SC, Wordsworth S. Hemodialysis for end-stage renal disease: a cost-effectiveness analysis of treatment-options. Int J Technol Assess Health Care 2005;21(1):32–39. DOI: 10.1017/S026646230505004X.
  47. Tong A, Palmer S, Manns B, Craig JC, Ruospo M, Gargano L, et al. Clinician beliefs and attitudes about home haemodialysis: a multinational interview study. BMJ Open 2012;2(6):e002146. DOI: 10.1136/bmjopen-2012-002146.
  48. Craig RG, Hunter JM. Recent developments in the perioperative management of adult patients with chronic kidney disease. Br J Anaesth 2008;101(3):296–310. Available from 10.1093/bja/aen203.
  49. Palmer SC, Saglimbene V, Mavridis D, Salanti G, Craig JC, Tonelli M, et al. Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis. Cochrane database Syst Rev 2014(12):CD010590. DOI: 10.1002/14651858.CD010590.pub2.
  50. Virani SA, Khosla A, Levin A. Chronic kidney disease, heart failure and anemia. Can J Cardiol 2008(24 Suppl):22B–24BB. DOI: 10.1016/S0828-282X(08)71026-2.
  51. Wang SM, Hsiao LC, Ting IW, Yu TM, Liang CC, Kuo HL, et al. Multidisciplinary care in patients with chronic kidney disease: a systematic review and meta-analysis. Eur J Intern Med 2015;26(8):640–645. DOI: 10.1016/j.ejim.2015.07.002.
  52. Strand H, Parker D. Effects of multidisciplinary models of care for adult pre-dialysis patients with chronic kidney disease: a systematic review. Int J Evid Based Healthc 2012;10(1):53–59. DOI: 10.1111/j.1744-1609.2012.00253.x.
  53. Painter P, Roshanravan B. The association of physical activity and physical function with clinical outcomes in adults with chronic kidney disease. Curr Opin Nephrol Hypertens 2013;22(6):615–623. DOI: 10.1097/MNH.0b013e328365b43a.
  54. Beathard GA. Role of interventional nephrology in the multidisciplinary approach to hemodialysis vascular access care. Kidney Res Clin Pract 2015;34(3):125–131. DOI: 10.1016/j.krcp.2015.06.004Available from:
  55. Kumpe DA, Cohen MA. Angioplasty/thrombolytic treatment of failing and failed hemodialysis access sites: comparison with surgical treatment. Prog Cardiovasc Dis 1992;34(4):263–278. DOI: 10.1016/0033-0620(92)90021-Q.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.